Evidence · Randomised trial
Neurodevelopmental Outcomes of Extremely Preterm Infants Randomized to Stress Dose Hydrocortisone.
- Bronchopulmonary dysplasia
- Eyes and hearing
- Mechanical ventilation
- Medical
- Neurodevelopmental follow-up
- Neurology
- Newborn hearing screening
- Respiratory
This paper is from 2015, more than five years ago. Newer evidence may have been published since.
Summary
Randomised controlled trial follow-up of 64 ventilator-dependent extremely low birth weight infants at high risk of bronchopulmonary dysplasia, given a tapering 7-day course of stress dose hydrocortisone or placebo between 10 and 21 days of age. The primary outcome was death or neurodevelopmental impairment at 18-22 months corrected age. Hydrocortisone did not significantly reduce death or impairment, nor the later use of respiratory support or medications. The authors suggest the findings may inform the design of future trials.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.